Antagonists of the brandykinin B1 receptor
US7605120B2 · kind B2 · utility
0Cited by
18References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 21, 2004 |
| Grant date | Oct 20, 2009 |
| Priority date | — |
| Expiry date | Nov 16, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K7/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to certain biologically active peptides and conjugated peptides which can be used as therapeutics or prophylactics against diseases or conditions linked to B1 as the causative agent. In a preferred embodiment of the invention biologically active PEG-conjugated peptides are provided. In one aspect of the present invention, pharmacologically active PEG-conjugated peptides of the present invention are useful to treat inflammation or pain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.